Get the Stockscreener App
208.45
3.29%
6.63
After Hours:
207.07
-1.38
-0.66%
Biogen Inc stock is traded at $208.45, with a volume of 1.21M.
It is up +3.29% in the last 24 hours and down -3.55% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$201.82
Open:
$200.96
24h Volume:
1.21M
Relative Volume:
1.00
Market Cap:
$30.77B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
22.37
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+1.38%
1M Performance:
-3.55%
6M Performance:
+12.40%
1Y Performance:
+57.68%
1-Day Range:
$199.93
$209.74
1-Week Range:
$199.58
$218.59
52-Week Range:
$127.00
$219.72
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
208.45 | 29.55B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,115.68 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.93 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
243.80 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.00 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.27 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen earnings on deck: Can Alzheimer’s drugs sustain momentum? By Investing.com - Investing.com Canada
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating - marketscreener.com
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo! Finance Canada
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS - AlphaStreet
BIIB|Biogen Inc|Price:200.140| - TradingKey
(BIIB) Volatility Zones as Tactical Triggers - Stock Traders Daily
Biogen Inc (BIIB) Institutional Confidence - TradingKey
Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB - MarketBeat
Biogen stock trades steady as Alzheimer’s franchise and pipeline shape earnings outlook - Ad-hoc-news.de
Biogen Inc (BIIB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biogen stock trades steady as Alzheimer’s data and revenue trends shape investor focus - AD HOC NEWS
Dimensional Fund Advisors LP Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales? - TradingView
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs - Endpoints News
Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis - TradingKey
First Trust Advisors LP Purchases 108,111 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027 - Endpoints News
At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Biogen CEO: Lessons from Biopharma on Leading Reinvention - WSJ
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg
Biogen (BIIB) to Post Earnings on Wednesday - MarketBeat
Mediolanum International Funds Ltd Invests $1.14 Million in Biogen Inc. $BIIB - MarketBeat
SEB Asset Management AB Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by Swiss National Bank - MarketBeat
Andra AP fonden Has $9.53 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BIIB Maintained by B of A Securities -- Price Target Lowered to $215 - GuruFocus
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
KBC Group NV Raises Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
Lobbying Update: $1,060,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.86% Potential Upside Amid Robust Therapeutic Portfolio - DirectorsTalk Interviews
Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
5.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):